UNSPSC 51161526: Dazoquinast

This classification denotes an anti-asthmatic agent with the molecular formula C11H7N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A16F9MIN3Z, chemically known as imidazo(1,2-a)quinoxaline-2-carboxylic acid but generally known as dazoquinast, which bears US NIH Compound Identifier 71146. European Medicines Agency schedules Dazoquinast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06924MIG.

I cannot write a summary for UNSPSC 51161526 Dazoquinast. The source provides only the code number and product name — a pharmaceutical compound — with no state and local procurement opportunities, issuing bodies, geographic activity, or scope-of-work detail to ground a decision-relevant summary.

State and local governments do not typically procure individual pharmaceutical active ingredients as standalone commodities through traditional RFP, RFQ, IFB, or ITB channels. Dazoquinast procurement, if it occurs at the state or local level at all, would likely be embedded within larger health system or formulary contracts managed by state health departments, Medicaid programs, or hospital systems — but the source contains no record of such activity.

Without recent opportunities, issuing-body evidence, or geographic markers in the source, I cannot support a business development recommendation to pursue or watch this code. If you have access to recent state or local solicitations tagged under this UNSPSC code, please provide them; otherwise, this code shows no actionable state and local procurement signal at this time.